3. Universal Health Services, Inc. (NYSE:UHS)
Investors with Long Positions (as of June 30): 50
Aggregate Value of Investors’ Holdings (as of June 30): $1.52 Billion
The number of hedge funds invested in Universal Health Services, Inc. (NYSE:UHS) out of the more than 700 that we track increased by six during the second quarter of 2015, while the aggregate investment value of these hedge funds rose by 64.38%. The Fortune 500 Company recently announced a dividend of $0.10 per share to shareholders of record as of September 1, with the dividend payable on September 15. This represents an annualized dividend yield of 0.29%. Besides the dividend, the hospital management company recently posted earnings per normalized share of $1.80, representing a 19.21% increase on a year-over-year basis. This year, the company’s shares have risen by an impressive 26.70%. At the close of the second quarter, Viking Global, headed by Andreas Halvorsen, emerged as the biggest shareholder of Universal Health Services, Inc. (NYSE:UHS) in our database. The fund initiated a new position in the stock of 1.22 million shares with a market value of $173.47 million at the end of the quarter.
2. Laboratory Corp. of America Holdings (NYSE:LH)
Investors with Long Positions (as of June 30): 52
Aggregate Value of Investors’ Holdings (as of June 30): $2.41 Billion
While the number of hedge funds we track that were long in Laboratory Corp. of America Holdings (NYSE:LH) fell by seven during the second quarter and the value of their aggregate ownership also slipped by 2.55%, the overall sentiment of the smart money was still bullish. The company recently announced that its VistaSeq Hereditary Cancer Panel, which is a novel, 27-gene panel designed for identifying patients with high risks of different cancers, is now available nationally. In its most recent quarterly results, Laboratory Corp. of America Holdings (NYSE:LH) posted earnings per share of $2.09, representing a year-over-year increase of $0.43. This year, the stock’s share price has gone up by a solid 11.05%, although it has been rather flat over the past three months. During the second quarter, Glenview Capital, managed by billionaire Larry Robbins, a staunch supporter of the healthcare industry, created a new position in the stock consisting of 3.98 million shares valued at $482.89 million. Decade Capital Management also opened a new position, of 222,435 shares with a market value of $26.96 million.
1. Endo International plc – Ordinary Shares (NASDAQ:ENDP)
Investors with Long Positions (as of June 30): 67
Aggregate Value of Investors’ Holdings (as of June 30): $4.46 Billion
During the second quarter, the number of hedge funds tracked by Insider Monkey that were long in Endo International plc – Ordinary Shares (NASDAQ:ENDP) increased by four and their investment value rose by 6.56%. Two Endo International patents relating to the extended-release version of its long-term pain drug Opana were recently upheld by a U.S. District Court, a move that will see generic versions of the drug sold by Allergan PLC (NYSE:AGN), among other companies, removed from the market, while those not yet released will be prevented from doing so. The court will decide whether Allergan will pay for damages relating to its infringement of said patents. In Endo International’s second quarter financial report, it posted a loss of $0.49 per share, compared to the profit per share of $0.25 that it posted last year. Year-to-date, the company’s stock price has gained 9.54%. At the end of the second quarter, OZ Management, headed by billionaire Daniel S. Och, was long in Endo International plc – Ordinary Shares (NASDAQ:ENDP) with 8.84 million shares valued at $704.09 million. Larry Robbins was also a notable shareholder of this stock, owning 8.84 million shares valued at $703.92 million on June 30.
Disclosure: None
